Rxrx stock forecast.

RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.

Rxrx stock forecast. Things To Know About Rxrx stock forecast.

Recursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors?Nov 9, 2023 · Recursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes. View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.

U.S. crude futures finish 1.2% higher $75.75 a barrel, the highest closing price since April 28, while Brent crude finishes above $80 for the first time since April 25, ending at $80.11. "Crude ...

Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ...

You can view all of the due diligence checks on RXRX's stock page. How is RXRX stock valued? You can. use many financial metrics, analyses, models, and charts to gauge RXRX's intrinsic value.Using relative valuations . metrics:RXRX; could be undervalued based on its P/B ratio of 3.35x, relative to Biotechnology industry P/B ratio of . 5.36xStock Price Forecast. The 7 analysts offering 12-month price forecasts for Recursion Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 35.00 and a low estimate of 9.00 ...Jul 12, 2023 · For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ... Both companies could tap into huge growth from the AI revolution in a few years. Schrödinger ( SDGR 2.90%) and Recursion Pharmaceuticals ( RXRX 4.40%) are both biotechs that want to use AI to ...

NSD:RXRX Detailed Stock Analysis, Stock Price Forecast, Analyst Ratings, Financial Analysis, Stock News & Historic Quotes

Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit margin

Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ...8 авг. 2023 г. ... RXRX+0.08 (+1.17%) After Hours. Share Share Article via ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...

The consensus price target of analysts on Wall Street is $16.00, which implies an increase of 65.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $35.00 respectively. As a result, RXRX is trading at a discount of -530.63% off the target high and -62.16% off the low.Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and …Jul 24, 2023 · As of July 24, 2023, 4:00 PM CST, Recursion Pharmaceuticals Inc’s stock price was $14.28. Recursion Pharmaceuticals Inc is down 7.69% from its previous closing price of $15.47. During the last market session, Recursion Pharmaceuticals Inc’s stock traded between $14.36 and $16.09. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Recursion’s Q1 2023 earnings show revenue as small but growing fast, growing from $5.3 million to $12.1 million year on year. With a net-loss of $65 million, Recursion is still an unprofitable ...

See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Find the latest Lexicon Pharmaceuticals, Inc. (LXRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term ...5 analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they anticipate the company's share price to reach $4.80 in the next year. This suggests a possible upside of 9.3% from the stock's current price.Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p ... 12 июл. 2023 г. ... Nvidia just invested millions into Recursion Pharmaceuticals, bolstering AI integration in biotech but also presenting risks for RXRX stock.Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...Find real-time RPRX - Royalty Pharma PLC stock quotes, company profile, news and forecasts from CNN Business.Research Recursion Pharmaceuticals' (Nasdaq:RXRX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past …

3 апр. 2023 г. ... Unity Stock New CEO Prioritizes Investors Over Stock Price. Jose Najarro ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August.

What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.

Company Description. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.According to our current RXRX stock forecast, the value of Recursion Pharmaceuticals, Inc. shares will drop by -9.72% and reach $ 6.59 per share by December 5, 2023. …July 12 (Reuters) - Chip designer Nvidia (NVDA.O) will invest $50 million to speed up training of Recursion's (RXRX.O) artificial intelligence models for drug discovery, the companies said on ...Nov 24, 2023 · The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors? Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations. Always seek sound financial advice from your consultant or financial advisor before investing in the stock market. I am a grapefruit, and the stock market is a casino. Disclosure: No positions current in this stock, planning to go Long, likely for between 100 to 500 shares.Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.The above table shows the analyst RXRX forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$7.39

GE stock has seen extremely strong gains of 85% from levels of $65 in early January 2021 to around $120 now, vs. an increase of about 20% for the S&P 500 over …Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buyWith stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.But the potential upside remains huge. Our roundtable group dug into her holdings and found three stocks that we particularly like. Here's why we're bullish on 10x Genomics ( TXG 2.96%), Beam ...Instagram:https://instagram. carl eschenbachvermilion energy stockblink stock forecasthedge fund ranking The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ... fcash fidelitycentral finance company Jul 13, 2023 · The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ... best small and mid cap etf Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price.